GP
ESPR icon

GLG Partners’s Esperion Therapeutics ESPR Stock Holding History

GLG Partners’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-15,363
Closed -$342K – 438
2015
Q4 		$342K Sell
15,363
-38,549
-72% -$973K 0.01% 400
2015
Q3 		$1.27M Buy
53,912
+24,412
+83% +$1.53M 0.03% 328
2015
Q2 		$2.41M Buy
+29,500
New +$2.89M 0.06% 277

Other funds holding ESPR

AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Pentwater Capital Management
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
BB Biotech
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Discovery Capital Management
Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

GLG Partners's ESPR Position: Q1 2016 in Review

GLG Partners sold out of Esperion Therapeutics (ESPR) in Q1 2016, closing a stake of 15,363 shares — an estimated $342K sold.

GLG Partners first reported a position in ESPR in Q2 2015 and held it in 3 quarters. The position peaked at $2.41M in Q2 2015. 109 funds tracked by Wall St. Rank hold ESPR as of Q1 2016.

  • GLG Partners reported no remaining Esperion Therapeutics position as of Q1 2016 after selling out during the quarter.
  • GLG Partners sold 15,363 Esperion Therapeutics shares in Q1 2016, an estimated $342K.
  • GLG Partners first reported a position in Esperion Therapeutics in Q2 2015 and held it in 3 quarters.
  • GLG Partners's Esperion Therapeutics position peaked at $2.41M in Q2 2015.
  • 109 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2016.

Based on GLG Partners's 13F filing for Q1 2016, filed 16 May 2016.